When Will Generic Semaglutide Be Available?

The short answer for Americans is uncomfortable: probably not until the early 2030s, and most likely 2032.

The longer answer is more interesting, because generic semaglutide already exists. It is on pharmacy shelves in India, approved in Canada and Brazil, and on the way in several dozen other countries. The United States is simply not one of them yet, for reasons that come down to patent law.

This is a market and policy explainer, not medical advice.

When does the US patent actually expire?

Novo Nordisk itself is the best source here. In its 2025 Form 20-F filing, the company stated that US compound patent expiry for Ozempic, Rybelsus and Wegovy is 2032 [1].

Independent reporting adds detail. Analyses of the patent estate put the core US compound patent expiration in December 2031, with practical generic entry modeled for 2032 [2]. Some commentary suggests that generic injectable semaglutide using the same formulation as Ozempic or Wegovy may face additional protection running toward 2033 absent a successful patent challenge or a settlement.

Treat all of those as estimates. Generic entry dates in the US are routinely shifted by patent litigation, settlements between brand and generic companies, and regulatory exclusivities. What is reliable is the shape: the US is a start-of-the-2030s market, not a 2020s one.

Where generic semaglutide already exists

Four major markets lost patent protection in the first half of 2026.

Canada

This one was partly an accident. Novo Nordisk’s Canadian data exclusivity on semaglutide expired January 4, 2026, and its core Canadian patent had already lapsed after missed maintenance fee payments — Bloomberg reporting cited a CA$250 payment [3].

Health Canada authorized Dr. Reddy’s Laboratories’ generic semaglutide injection on April 28, 2026, making Canada the first G7 country with an approved generic [4]. The approval covers 2 mg/pen and 4 mg/pen formulations for type 2 diabetes in adults.

Apotex followed on May 1, 2026 with Apo-Semaglutide Injection, a generic Ozempic for type 2 diabetes, developed with India’s Orbicular Pharmaceutical Technologies [5]. Dr. Reddy’s product reached Canadian pharmacies on May 15, 2026 [5].

Then on June 29, 2026 Health Canada authorized the first generic semaglutide for weight loss: Apotex’s Sevmia, a generic of Wegovy, indicated for once-weekly chronic weight management in patients 12 and older [15]. That was the third generic semaglutide approved in Canada, and Health Canada said six other generic semaglutide submissions remained under review at that point, with more decisions expected.

On price: under Canada’s pan-Canadian Pharmaceutical Alliance framework, a first generic is typically priced at 85%, 75% or 55% of the brand depending on provincial agreements, with deeper cuts as more generics arrive. Health Canada notes generics are commonly 45% to 90% cheaper than brands over time [6]. Ozempic’s Canadian list price is roughly CA$223 to CA$250 for four weeks before markups.

India

India produced the fastest, deepest price collapse. The semaglutide patent expired March 20, 2026, and roughly ten companies launched within days: Sun Pharma, Dr. Reddy’s, Zydus, Glenmark, Alkem, Natco, Eris, Torrent and others [7].

Reported monthly prices landed between about 1,290 and 8,000 rupees, against Novo Nordisk’s Indian retail range of 8,800 to 16,400 rupees — discounts approaching 90% [8]. Vials were cheapest; pen devices carried a premium. Sun Pharma launched its diabetes brand from about 750 rupees a week, roughly $8, and its weight-management brand from about 900 rupees a month. Natco’s vial came in around 1,250 rupees a month.

Novo Nordisk responded by cutting its branded Wegovy price in India by up to 48%, according to secondary reporting.

Brazil

Brazil’s patent expired in March 2026. Anvisa approved EMS’s Ozivy, the country’s first semaglutide injector pen, on May 26, 2026, to be made at an EMS plant in Sao Paulo state with capacity for up to 40 million pens a year [9]. Five other synthetic semaglutide applications and one biological version were under review. Sun Pharma won a separate Brazilian approval in July 2026.

China

China’s compound patent expired the same day as India’s, March 20, 2026. But as of late April 2026, no Chinese generic had been approved and Novo Nordisk still held exclusive control of the market, with eleven applications in review [10]. Hangzhou Jiuyuan Gene Engineering filed for approval of Jikeqin, a Wegovy biosimilar. Some Chinese analysts expect approvals in 2027.

Can Americans get any of this?

No, and it is worth being blunt about it.

Products approved by Health Canada, India’s Drugs Controller General or Brazil’s Anvisa are not FDA approved. They cannot legally be sold in the United States. FDA rules generally bar individuals from importing prescription drugs that are not FDA approved, including foreign-labeled versions of drugs that are approved here [11].

The generic manufacturers are not trying to sell into the US either. Dr. Reddy’s chief executive told the BBC the company has applied for approval in more than 80 countries and expects its generic GLP-1 in South America, Africa and most of Asia, but explicitly not in the US, UK or Europe — patents block it [12]. He described the US as “the last one,” when the patent expires.

Is compounded semaglutide a generic?

No, and this confusion costs people money and sometimes safety.

A generic is an FDA-approved product that has been shown to be equivalent to the brand in active ingredient, strength, dosage form and performance. Generic substitution is a regulated process.

Compounded semaglutide is a preparation made by a pharmacy. It is not FDA approved, is not reviewed for safety, effectiveness or manufacturing quality, and carries no equivalence finding.

Compounded GLP-1s became widely available only because semaglutide was on the FDA drug shortage list from 2022, which temporarily let pharmacies make copies. That door closed. The FDA declared the semaglutide injection shortage resolved on February 21, 2025, with wind-down deadlines of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. Compounders sued and lost their preliminary injunction motions [13].

On April 1, 2026 the FDA restated the rules. Semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list, which effectively shuts outsourcing facilities out. Under 503A, the agency said it does not intend to act against a compounder filling four or fewer prescriptions of an essentially-a-copy product in a calendar month, and warned that combining semaglutide with something like vitamin B12 does not by itself escape the essentially-a-copy finding when strengths are within 10% of the commercial products [13]. On April 30, 2026 the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.

How much will a US generic actually save?

Less than people expect at first, then a lot.

The pattern is well established. A single first generic with limited competition prices modestly below the brand. Prices fall steeply only once several manufacturers are approved and competing. India’s 90% collapse happened because about ten companies launched at once. Canada’s framework starts the first generic at 75% to 85% of brand.

There is also a complicating factor specific to GLP-1s: the pen device. Several sources note that injection pen manufacturing capacity is a real constraint, which is why Indian vial formulations undercut pen formulations so sharply. A US generic may arrive in a less convenient format first.

What if you need something cheaper now?

The good news is that the US market has already moved a long way without generics.

Branded semaglutide cash prices in the US now run $149 to $499 a month (verified 2026-09-14) depending on product and dose. That is a range, not a single price. The Wegovy pill and the Ozempic pill start at $149. The pens run $199 for the first two fills at the starter doses and $349 after that. Wegovy HD is $399. A 12-month subscription can bring the pen to $249.

Novo Nordisk has also announced it will cut the list price to $675 a month for Wegovy, Ozempic and Rybelsus effective January 1, 2027 [14], which matters for anyone paying coinsurance or working through a deductible.

And competition within the class is doing some of the work generics normally do. Eli Lilly’s Zepbound (tirzepatide) sells at $299 to $449 a month self-pay through LillyDirect if you refill within 45 days, and its Foundayo (orforglipron) pill runs $149 to $349 depending on dose. These are different molecules from semaglutide, not substitutes in a clinical sense, but they compete on price.

The bottom line

If you are waiting for generic semaglutide in the United States, plan on the early 2030s. Novo Nordisk says 2032; analysts say 2032 to 2033 depending on which patents hold.

Between now and then, the realistic path to a lower price is the branded self-pay market, insurance coverage if you can get it, and for people on Medicare, the GLP-1 Bridge. Foreign generics are not a legal option for US consumers, and compounded semaglutide is neither a generic nor broadly legal anymore.

Sources

1. With Novo’s semaglutide going off patent, Indian drugmakers set to launch their cheaper generics — Fierce Pharma, 2026
2. Looming GLP-1 drug patent expirations draw generics firms — Chemical & Engineering News, 2025-12
3. Ozempic generics set to test Canada’s drug budgets — Benefits and Pensions Monitor, 2026
4. Canada becomes the first G7 country to approve a generic version of semaglutide — Health Canada, 2026-04-28
5. First Generic Ozempic Approved in Canada for Dr Reddy’s and Apotex — Pearce IP, 2026-04-29
6. Canada approves first generic version of Ozempic — Reuters, 2026-04-28
7. Generic Semaglutide Launches in India — Pearce IP, 2026-03-21
8. India is launching cheap weight-loss drugs — CNBC, 2026-03-23
9. Brazil approves first generic semaglutide pen after Ozempic patent expiry — Reuters, 2026-05-26
10. Semaglutide Patent Expires Today: China’s fastest generic filers — VCBeat Health, 2026-03-20
11. Personal Importation — FDA, 2025-08-18
12. Why Canadians can now get cheaper generic Ozempic and Americans can’t — BBC News, 2026
13. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, 2026-04-01
14. Novo Nordisk announces significant reduction in US list price — Novo Nordisk, 2026-02-24
15. Canada approves first generic semaglutide for weight loss — Health Canada, 2026-06-29